Discounted Cash Flow Rating

Neutral

Return on Equity Rating

Buy

Debt to Equity Rating

Neutral

Price to Earnings Rating

Sell

Analyst Rating

Buy

Simple Moving Average

Strong Buy

Exponential Moving Average

Strong Buy

Relative Strength Index

Buy

Standard Deviation

Strong Buy

Williams %R

Strong Buy

Average Directional Index

Neutral

Insider Trading

Neutral

Wall Street Data Solutions Rating

Buy

A

BioMarin Pharmaceuticals Inc (BMRN)

Pharmaceutical Preparations

http://www.bmrn.com

BioMarin's focus is on rare-disease therapies. Genzyme (now part of Sanofi) markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU (in addition to long-standing U.S. rights, BioMarin has reacquired international rights for Kuvan and Palynziq from Merck KGaA). Voxzogo (vosoritide) was approved in achondroplasia in 2021. BioMarin's Roctavian (hemophilia A gene therapy) was approved in Europe in 2022 and in the U.S. in 2023.

105 DIGITAL DRIVE
NOVATO, CA

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

07/23/1999

Market Cap

17,005,009,560

Shares Outstanding

188,370,000

Weighted SO

188,368,171

Total Employees

N/A

Upcoming Earnings

07/29/2024

Similar Tickers

SGEN --.--%

ALNY --.--%

EXEL --.--%

HALO --.--%

ARWR --.--%

INCY --.--%

IONS --.--%

APLS --.--%

PCVX --.--%

Beta

0.3190

Last Div

0.0000

Range

73.68-99.56

Chg

0.1400

Avg Vol

2435466

Mkt Cap

17005009560

Exch

NASDAQ

Country

US

Phone

415 506 6700

DCF Diff

77.0236

DCF

12.3864

Div Yield

0.0000

P/S

6.5665

EV Multiple

52.1174

P/FV

3.2123

Div Yield %

0.0000

P/E

66.1797

PEG

7.0850

Payout

0.0000

Current Ratio

3.0540

Quick Ratio

1.9450

Cash Ratio

0.9108

DSO

97.4257

DIO

771.2744

Op Cycle

868.7001

DPO

167.7355

CCC

700.9646

Gross Margin

0.7837

Op Margin

0.0859

Pretax Margin

0.1153

Net Margin

0.0991

Eff Tax Rate

0.1409

ROA

0.0363

ROE

0.0508

ROCE

0.0371

NI/EBT

0.8591

EBT/EBIT

1.3432

EBIT/Rev

0.0859

Debt Ratio

0.1556

D/E

0.2080

LT Debt/Cap

0.1010

Total Debt/Cap

0.1722

Int Coverage

22.5756

CF/Debt

0.2991

Equity Multi

1.3369

Rec Turnover

3.7464

Pay Turnover

2.1760

Inv Turnover

0.4732

FA Turnover

2.4596

Asset Turnover

0.3664

OCF/Share

1.7298

FCF/Share

1.1193

Cash/Share

6.4401

OCF/Sales

0.1270

FCF/OCF

0.6471

CF Coverage

0.2991

ST Coverage

0.6505

CapEx Coverage

2.8336

Div&CapEx Cov

2.8336

P/BV

3.2123

P/B

3.2123

P/S

6.5665

P/E

66.1797

P/FCF

79.9093

P/OCF

51.6356

P/CF

51.6356

PEG

7.0850

P/S

6.5665

EV Multiple

52.1174

P/FV

3.2123

DPS

0.0000

Latest Headlines (EST)

GlobeNewswire Inc. Jun 20, 21:00 Inozyme Pharma, Inc. Announces Postponement of 2025 Annual Meeting of Stockholders Benzinga Sep 22, 21:04 Novo Nordisk, Chewy And FedEx Are Among Top 10 Large Cap Losers Last Week (Sept 15-Sept 21): Are The Others In Your Portfolio? The Motley Fool Jan 20, 05:06 4 Marvelous Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip The Motley Fool Jan 20, 05:06 4 Marvelous Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip MarketWatch Dec 23, 06:50 Biotech stocks set for a rebound in 2024, analysts say MarketWatch Dec 23, 06:50 Biotech stocks set for a rebound in 2024, analysts say MarketWatch Dec 22, 11:06 Biotech stocks set for a rebound in 2024, analysts say Benzinga Dec 21, 12:00 Cracking The Code: Understanding Analyst Reviews For Biomarin Pharmaceutical The Motley Fool Dec 02, 05:06 4 Preeminent Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip The Motley Fool Dec 02, 05:06 4 Preeminent Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip The Motley Fool Nov 04, 05:06 4 Unique Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip The Motley Fool Nov 04, 05:06 4 Unique Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip Zacks Investment Research Nov 01, 18:30 BioMarin (BMRN) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

Revenue Product Segmentation